BMY - Bristol-Myers Squibb Company

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by T0rm3nted, Apr 28, 2016.

  1. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,460
    Likes Received:
    3,278
    [​IMG]
    Bristol-Myers Squibb (BMY), often referred to as BMS, is an American pharmaceutical company, headquartered in New York City.

    Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."

    BMS' primary R&D sites are located in Lawrence Township, New Jersey (formerly Squibb, near Princeton) and Wallingford, Connecticut (formerly Bristol-Myers), with other sites in Hopewell and New Brunswick, New Jersey, and in Swords, Ireland, Braine-l'Alleud, Belgium, Tokyo, Japan and Bangalore, India.
     
  2. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,460
    Likes Received:
    3,278
    Reported before open today (4/28/16)
    Earnings: EPS $0.74 Revenue $4.4B
    Estimates: EPS $0.66 Revenue $4.2B
     
    Tiptopptrader likes this.
  3. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,460
    Likes Received:
    3,278
    Ex-Div-Date: 6/29/16
    Payment Date: 8/1/16
    Dividend: $0.38
    Current Price: $72.64
    Annual Yield: 2.09%
     
  4. bigbull

    bigbull Active Member

    Joined:
    Jul 12, 2016
    Messages:
    253
    Likes Received:
    130
    There may be an opportunity on a trade down to $59.18 back up to $61.78.

    The engulfing candlestick is evident of more side-ways action in the interim as institutions gobble up positions and sell calls to finance trades. They are in no need to price this back at the highs.
     
  5. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,546
    Likes Received:
    3,544
    Ouch, sell off continues, that is one hell of a drop!

    Bristol-Myers Squibb (BMY) led the health care sector lower on Monday after Credit Suisse cut its rating to neutral from outperform. The drug company slumped on Friday in the second-biggest one-day drop in its history after disappointing trial results for a highly anticipated lung cancer treatment.
     
  6. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,546
    Likes Received:
    3,544
    Hmm, Sept calls for a bounce soon.

    What do you think?
     
  7. anotherdevilsadvocate

    anotherdevilsadvocate Well-Known Member

    Joined:
    Apr 3, 2016
    Messages:
    4,333
    Likes Received:
    3,380
    68 calls?

    weekly:
    [​IMG]
     
  8. leonx81

    leonx81 Well-Known Member

    Joined:
    Apr 4, 2016
    Messages:
    1,119
    Likes Received:
    563
    tempting to pick up some calls. :D
     
  9. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,546
    Likes Received:
    3,544
    Wait, are you all going to do it now?

    Because then its sure to fail! lol
     
  10. leonx81

    leonx81 Well-Known Member

    Joined:
    Apr 4, 2016
    Messages:
    1,119
    Likes Received:
    563
    I just picked up some more AMD JAN 20 $8 calls instead, thus I will let you guys have all the fun. :D
     
  11. bigbull

    bigbull Active Member

    Joined:
    Jul 12, 2016
    Messages:
    253
    Likes Received:
    130
    Calls and puts are cheap, but their cheap for a reason -- no one is expecting a major move one way or another.
    With volatility getting cheaper with each passing day, I think its best to buy some long dated calls if you trust BMY will bounce back at some point. In fact, long dated calls is were your seeing the bulk of the activity.

    If this can trade down to $58 - $59, I would buy some for a longer term hold. Otherwise, I would stick with the stock as unattractive of an alternative as it may seem.

    $58 - $60 likely represents a good spot to go long the stock long term, but

     
    leonx81 likes this.
  12. leonx81

    leonx81 Well-Known Member

    Joined:
    Apr 4, 2016
    Messages:
    1,119
    Likes Received:
    563
    Anyone in? I picked up a few AUG 19 $61 calls before the closing yesterday. :D

    upload_2016-8-9_11-24-39.png
     
  13. Tiptopptrader

    Tiptopptrader Well-Known Member

    Joined:
    Mar 31, 2016
    Messages:
    4,895
    Likes Received:
    1,124
  14. LloydWCoutee

    LloydWCoutee Active Member

    Joined:
    May 4, 2016
    Messages:
    721
    Likes Received:
    58
    funny, it is actually down becuz of Merck's results today...man, this will bounce right back quicker than backerball
     
  15. fidelgeorge

    fidelgeorge Well-Known Member

    Joined:
    Apr 15, 2016
    Messages:
    971
    Likes Received:
    393
    We've got a huge gap to fill. BMY is long established and more than capable. Clinical trial setbacks happen. Undervalued. Long hold.
    bmy.png
     
  16. Tiptopptrader

    Tiptopptrader Well-Known Member

    Joined:
    Mar 31, 2016
    Messages:
    4,895
    Likes Received:
    1,124
    Up on Q3 beat

    upload_2016-10-27_9-16-3.png
     
  17. Tiptopptrader

    Tiptopptrader Well-Known Member

    Joined:
    Mar 31, 2016
    Messages:
    4,895
    Likes Received:
    1,124
    Bristol-Myers shares fall on lung cancer timeline setback

    upload_2017-1-20_12-47-38.png
     
  18. Marvan

    Marvan Well-Known Member

    Joined:
    Mar 16, 2019
    Messages:
    966
    Likes Received:
    98
    The U.S. Food and Drug Administration recently acknowledged Bristol Myers Squibb's application for deucravacitinib to treat moderate-to-severe psoriasis.

    Key Points
    • An FDA approval would open up deucravacitinib to a market of several hundred thousand psoriasis patients.
    • This indication could generate nearly $700 million in annual sales for Bristol Myers Squibb.
    • The company can provide income investors with a market-smashing 3.5% dividend yield.

    In late November, the U.S. Food and Drug Administration (FDA) announced that it accepted Bristol Myers Squibb's (NYSE:BMY) New Drug Application for deucravacitinib as a treatment for patients with moderate-to-severe psoriasis.

    With the FDA targeting a decision on deucravacitinib in September 2022, let's dive into the drug's efficacy and sales potential if approved.

    Clinical results that beat out Otezla
    Paraphrasing the Mayo Clinic, psoriasis is a skin disease that results in red and itchy patches, especially on the knees, elbows, and scalp. The symptoms of psoriasis can include swollen and stiff joints, dry and cracked skin, and itching and burning skin.

    Psoriasis can range from mild to severe in nature. Using the Psoriasis Area and Severity Index (PASI), the extent of the disease is measured by the surface area and severity for six regions of the body. PASI scores range from 0 to 72, according to WebMD. A PASI score greater than 10 is generally a moderate-to-severe case of psoriasis.

    The first-line treatment for psoriasis is usually topical treatments. However, patients don't often comply for various reasons, which is evidenced by 50% to 70% compliance rates for topical treatments. If patients don't adequately respond to topical treatments, those medications are often discontinued or another treatment is added.


    Deucravacitinib is one investigational drug that could soon become a part of many treatment regimens for patients struggling to manage their psoriasis. Bristol Myers Squibb enrolled nearly 1,700 moderate-to-severe psoriasis patients into two phase 3 clinical trials to examine the efficacy of deucravacitinib against placebo and Amgen's (NASDAQ:AMGN) blockbuster psoriasis and psoriatic arthritis drug Otezla. Half of the patients enrolled in the studies were randomized to receive 6 milligrams of deucravacitinib once daily, whereas the other half received either a placebo or 30 milligrams of Otezla twice daily.

    Up to 59% of patients taking deucravacitinib achieved PASI 75 at week 16. This was significantly higher than the 40% rate for those receiving Otezla and nearly 13% of those taking a placebo. For context, PASI 75 means that a psoriasis patient's PASI score was reduced by at least 75%. The PASI score is calculated by accounting for a patient's PASI score both before and during treatment.

    Significant sales potential
    Deucravacitinib demonstrated itself to be a highly effective treatment for moderate-to-severe psoriasis patients. But how much would a potential moderate-to-severe psoriasis indication mean for pharma stock Bristol Myers Squibb in terms of annual revenue if approved?

    First, there are roughly 7.4 million adults in the U.S. with psoriasis. What's more, it's estimated that about 20% of those patients have moderate-to-severe disease, which works out to nearly 1.5 million patients. Next, I'll assume that 30% of patients with moderate to severe disease aren't adequately controlling their condition. So, Bristol Myers Squibb's potential patient population is realistically around 450,000.


    Because the market is flush with psoriasis treatments like Johnson & Johnson's (NYSE:JNJ) Tremfya, AbbVie's (NYSE:ABBV) Humira, and Amgen's Otezla, I expect that deucravacitinib will achieve a 6% patient share. This equates to 27,000 patients.

    While pricing information for deucravacitinib won't be available until after it is likely approved by the FDA, I'll use Otezla's $47,000 annual list price as a guide. Because health insurers negotiate this amount significantly lower, I'll assume an annual net price of $25,000 per patient.

    This works out to almost $700 million in additional annual sales for Bristol Myers Squibb. By itself, this is less than 2% of the company's projected $46.5 billion in sales. But with deucravacitinib in clinical trials for inflammatory bowel disease and psoriatic arthritis, Bristol Myers Squibb anticipates that the drug will reach peak annual sales of $4 billion.

    A top-notch income stock at an attractive valuation
    Bristol Myers Squibb is up 14% in the past month, which raises the following question: Should income investors buy the stock?


    The stock trades at a forward P/E ratio of only 7.9, which appears to be an appealing price considering that analysts are forecasting 6% annual non-GAAP earnings per share (EPS) growth over the next five years.

    And the stock offers investors a well-covered, market-topping 3.5% dividend yield. Bristol Myers Squibb's high yield, decent growth prospects, and cheap valuation make it a stock that income investors should consider buying for their portfolios.

    https://www.fool.com/investing/2022...hoo-host&utm_medium=feed&utm_campaign=article
     
  19. Marvan

    Marvan Well-Known Member

    Joined:
    Mar 16, 2019
    Messages:
    966
    Likes Received:
    98
    Bristol Myers Squibb is rewarding its shareholders with a huge dividend hike and a massive share-buyback program.
    [​IMG]
    Kody Kester
    (TMFkodyk123)
    Jan 4, 2022 at 6:15AM
    Key Points
    • The pharma stock's capital return program is funded by its remarkable ability to mint free cash flow.
    • Bristol Myers Squibb's balance sheet is in decent condition.
    • The stock is trading at a forward P/E ratio of just under 8.


    Two signs that a company is focused on creating significant value for its shareholders are when the company boosts its dividend and when it repurchases its shares at attractive valuations.

    Pharma stock Bristol Myers Squibb (NYSE:BMY) recently announced a 10.2% hike in its quarterly dividend to $0.54 per share. And if that wasn't enough to please shareholders, the company also authorized an additional $15 billion in share buybacks -- or nearly 11% of its $139 billion market capitalization.

    This ambitious capital return plan raises two questions: Can the company afford it? And is the stock currently a buy? Let's dig into Bristol Myers Squibb's cash flow capabilities, balance sheet, and valuation to try to answer these questions.


    Bristol Myers Squibb is a cash flow machine
    At the heart of Bristol Myers Squibb's tremendous capital return program for shareholders is the company's anticipated production of between $45 billion and $50 billion in cumulative free cash flow (FCF) for shareholders from 2021 through 2023. That's approximately a third of its market cap in free cash flow in just three years, which would be amazing. But because some companies tend to overpromise and underdeliver, let's delve into whether this forecast is grounded in reality, or the management team has been wearing rose-colored glasses.

    For the first three quarters, Bristol Myers Squibb had generated $12.1 billion in operating cash flow against $653 million in capital expenditures. In just nine months, the company has provided $11.5 billion in free cash flow for shareholders. At the rate it's going, this would work out to $46 billion in free cash flow between 2021 and 2023. Bristol Myers Squibb is positioned to hit the low end of its FCF target before even considering another important lever that it can use to bump its free cash flow even higher.


    That lever is its $13.5 billion cash position as of the most recent quarter. This gives Bristol Myers Squibb flexibility to execute the purchase of a medium-sized company if it believed such an acquisition target could fit well within its existing drug portfolio.

    Bristol Myers Squibb's 2021 free cash flow easily covered its $3.5 billion in share buybacks executed and $3.3 billion in dividends paid during that time. Simply put, the company is a free cash flow monster capable of affording its market-beating 3.5% dividend yield and significant share repurchases.

    The balance sheet is solid
    Bristol Myers Squibb is throwing off more than enough free cash flow to fund its dividend and share repurchases. But could the state of its balance sheet force the stock to cut back on the dividend or on share repurchases?

    The company's ratio of debt to earnings before interest, taxes, depreciation, and amortization (EBITDA) is 2.2. Note that the company's EBITDA has varied wildly for more than a decade but the Q3 results are in line with its 13-year median of 2.2. While Bristol Myers Squibb's debt-to-EBITDA ratio is weaker than Johnson & Johnson's of 1.5, it's stronger than AbbVie's of 3.2.


    Despite its generous capital allocation, Bristol Myers Squibb was able to reduce its long-term debt by $8.7 billion year-to-date (through Sep. 30, 2021), to $39.7 billion in the quarter. This indicates that the company can take a balanced approach to its dividend and share-repurchase activity, as well as to debt repayment.

    Quality at a reasonable valuation
    Bristol Myers Squibb appears to be a financially healthy business. But is it worth buying at the current valuation? Well, its forward price-to-earnings (P/E) ratio of 7.9 is considerably lower than the drug manufacturing industry average of 11.4. This implies that the stock could be an undervalued dividend growth stock for income investors.

    Let's also weigh its growth prospects against its industry. The company's forecast 6% annual earnings growth over the next five years is moderately lower than the industry average of 10%. This justifies a somewhat lower valuation multiple until the company proves that it can overcome looming patent cliffs on its top three drugs -- Revlimid, Eliquis, and Opdivo.

    However, if you're an income investor who believes Bristol Myers Squibb's pipeline will be sufficient to move past its current top-selling drugs, the current $63 share price would seem to provide a nice buying opportunity.

    https://www.fool.com/investing/2022...hoo-host&utm_medium=feed&utm_campaign=article
     
  20. Marvan

    Marvan Well-Known Member

    Joined:
    Mar 16, 2019
    Messages:
    966
    Likes Received:
    98

Share This Page